LeafNLP Demos
Back to explore

Report #2886889

Received Feb 25, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
MO
Recovered
Unknown
Vaccinated
Jan 23, 2026
Onset
Feb 4, 2026
Days to onset
12
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
HPV9HPV (GARDASIL 9)MERCK & CO. INC.1——
HPV9HPV (GARDASIL 9)MERCK & CO. INC.2——

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

No additional AE/ no PQC; HCP reports that the patient received their second dose of GARDASIL 9 at a shorter than recommended interval. No additional information was provided. No additional AE/ no PQC Date of first dose: 01/23/2026 Date of second dose: 02/04/2026; This Spontaneous report was received from other health professional and referred to a 44 -year-old patient of unknown gender. The patient's medical history, past medications and concomitant medications were not reported. On 23-Jan-2026, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9)(Dose Text: 0.5 ml/ series) (lot number, expiration date, administration route and anatomical location were not reported) as prophylaxis. Later, on 04-Feb-2026, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9)(Dose Text: 0.5 ml/ series) (lot number, expiration date, administration route and anatomical location were not reported) as prophylaxis. The reporter stated that the patient received their second dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9) at a shorter than recommended interval. No additional information was provided, and no additional adverse events were reported.